{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:37:36Z","timestamp":1792795056458,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Transarterial chemoembolization (TACE) is a primary treatment for intermediate to advanced hepatocellular carcinoma (HCC); however, cancer-related fatigue (CRF) is a prevalent and distressing symptom following TACE that significantly impairs patients' recovery and health-related quality of life. This review aimed to systematically summarize the current evidence on CRF screening, assessment, and non-pharmacological interventions specifically tailored to the post-TACE HCC population, and to propose an integrated, nurse-led clinical management framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review was conducted by systematically searching PubMed, Web of Science, and CNKI for literature published up to April 2026. The search encompassed peer-reviewed original research articles (including randomized controlled trials, cohort studies, cross-sectional studies, and meta-analyses), clinical practice guidelines, and expert consensus reports. The level of evidence for each intervention category was evaluated using the Oxford Centre for Evidence-Based Medicine (OCEBM) grading system. The literature search focused on CRF epidemiology, pathophysiology, validated assessment tools, non-pharmacological interventions (including exercise, psychosocial support, nutritional management, and traditional Chinese medicine therapies), and nursing management models in HCC patients following TACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CRF following TACE is a multifactorial symptom driven by treatment-induced inflammation, hepatic dysfunction, and psychological distress. Validated screening tools, including the Brief Fatigue Inventory (BFI), Cancer Fatigue Scale (CFS), and EORTC QLQ-C30 fatigue subscale, are recommended for routine use, though to the best of our knowledge, no CRF assessment tool developed specifically for the post-TACE HCC population has been validated to date. A structured screening pathway encompassing baseline assessment, perioperative monitoring, and long-term follow-up was identified as essential for early detection. Among non-pharmacological interventions, individualized exercise prescriptions (aerobic and resistance training) have been most consistently supported across randomised trials and meta-analyses for alleviating CRF, followed by cognitive behavioral therapy, mindfulness-based stress reduction, and nutritional support. Traditional Chinese medicine approaches, including acupoint massage, auricular acupressure, and moxibustion, showed preliminary potential but require further high-quality validation. A nurse-led multidisciplinary care model integrating assessment, individualized intervention planning, and continuous coordination has been proposed as a promising operational framework for CRF management, endorsed by international CRF practice frameworks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Effective management of CRF after TACE requires a comprehensive, evidence-based approach spanning standardized screening, multimodal non-pharmacological interventions, and a nurse-coordinated multidisciplinary care model. Integrating routine CRF assessment into standard TACE clinical pathways and developing TACE-specific assessment tools are priorities for future research and clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-11380-9","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:37:59Z","timestamp":1792733879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in assessment systems and non-pharmacological intervention strategies for cancer-related fatigue following transarterial chemoembolization in hepatocellular carcinoma: a narrative review"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4630-7553","authenticated-orcid":false,"given":"Shiying","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2835-2545","authenticated-orcid":false,"given":"Xuelei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9464-8215","authenticated-orcid":false,"given":"Yali","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8547-4543","authenticated-orcid":false,"given":"Teng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3082-6574","authenticated-orcid":false,"given":"Jiamin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0425-6679","authenticated-orcid":false,"given":"Lin","family":"Shentu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"2","key":"11380_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1272\/jnms.JNMS.2022_89-224","volume":"89","author":"Y Kawano","year":"2022","unstructured":"Kawano Y, Kaneya Y, Aoki Y et al (2022) Medical treatment for hepatocellular carcinoma in Japan. J Nippon Med Sch 89(2):154\u2013160. https:\/\/doi.org\/10.1272\/jnms.JNMS.2022_89-224","journal-title":"J Nippon Med Sch"},{"issue":"10","key":"11380_CR2","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.4103\/jfmpc.jfmpc_2347_20","volume":"10","author":"H Ghanaati","year":"2021","unstructured":"Ghanaati H, Mohammadifard M, Mohammadifard M (2021) A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. J Family Med Prim Care 10(10):3553\u20133560. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_2347_20","journal-title":"J Family Med Prim Care"},{"issue":"2","key":"11380_CR3","first-page":"29","volume":"11","author":"CQ Wang","year":"2021","unstructured":"Wang CQ (2021) Research progress on nursing interventions for cancer-related fatigue in liver cancer patients. Yi Yao Qian Yan 11(2):29\u201330 (Chinese)","journal-title":"Yi Yao Qian Yan"},{"key":"11380_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113941","author":"WZ Zhang","year":"2025","unstructured":"Zhang WZ, Han JQ, Chin KY, Zakaria R, Hassan NH (2025) Determinants of health-related quality of life after transarterial chemoembolization in hepatocellular carcinoma patients: a systematic review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14113941","journal-title":"J Clin Med"},{"key":"11380_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573505","volume":"16","author":"W Zhang","year":"2025","unstructured":"Zhang W, Liu Z, Liu H et al (2025) The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis. Front Immunol 16:1573505. https:\/\/doi.org\/10.3389\/fimmu.2025.1573505","journal-title":"Front Immunol"},{"key":"11380_CR6","unstructured":"Li D, Pang Y, Xu L, Xu X (2021) Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: a meta-analysis. J BUON 26(4):1355\u20131364"},{"key":"11380_CR7","doi-asserted-by":"publisher","unstructured":"Chen X, Huang M, Liu R, Chan LWC (2026) Clinical efficacy of immunotherapy in combination of locoregional therapies for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol 17:1706375. Published 2026. https:\/\/doi.org\/10.3389\/fimmu.2026.1706375","DOI":"10.3389\/fimmu.2026.1706375"},{"issue":"5","key":"11380_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1159\/000525500","volume":"11","author":"M Ikeda","year":"2022","unstructured":"Ikeda M, Arai Y, Inaba Y et al (2022) Conventional or drug-eluting beads? Randomized controlled study of chemoembolization for hepatocellular carcinoma: JIVROSG-1302. Liver Cancer 11(5):440\u2013450. https:\/\/doi.org\/10.1159\/000525500","journal-title":"Liver Cancer"},{"key":"11380_CR9","doi-asserted-by":"publisher","unstructured":"Xia LQ, Lin ZZ, Wu JJ et al (2025) Correlation between cancer-related fatigue and psychological status in liver cancer patients with cirrhosis. Ai Zheng Jin Zhan 23(17):2073\u20132075,2079. Chinese. https:\/\/doi.org\/10.11877\/j.issn.1672-1535.2025.23.17.20","DOI":"10.11877\/j.issn.1672-1535.2025.23.17.20"},{"issue":"11","key":"11380_CR10","first-page":"1813","volume":"32","author":"SY Yang","year":"2021","unstructured":"Yang SY (2021) Correlation between postoperative cancer-related fatigue and self-efficacy in liver cancer patients. Xian Dai Zhen Duan Yu Zhi Liao 32(11):1813\u20131814 (Chinese)","journal-title":"Xian Dai Zhen Duan Yu Zhi Liao"},{"key":"11380_CR11","doi-asserted-by":"publisher","unstructured":"Liu YH, Pan JY, Jia L (2004) Correlation analysis between cancer-related fatigue and social support in liver cancer patients. Guang Zhou Yi Yao 35(3):18\u201320. Chinese. https:\/\/doi.org\/10.3969\/j.issn.1000-8535.2004.03.008","DOI":"10.3969\/j.issn.1000-8535.2004.03.008"},{"key":"11380_CR12","doi-asserted-by":"publisher","unstructured":"Guo B, Liu J, Zhao LJ et al (2024) Influencing factors and prediction model of postoperative cancer-related fatigue in primary liver cancer patients. Xian Dai Sheng Wu Yi Xue Jin Zhan 24(9):1707\u20131711,1644. https:\/\/doi.org\/10.13241\/j.cnki.pmb.2024.09.021. Chinese","DOI":"10.13241\/j.cnki.pmb.2024.09.021"},{"key":"11380_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/JHC.S428980","volume":"10","author":"SQ Li","year":"1811","unstructured":"Li SQ, Wu JY, Wu JY et al (2023) Transarterial chemoembolization plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with main trunk portal vein tumor thrombus: a multicenter retrospective study. J Hepatocell Carcinoma 10:1799\u20131811. https:\/\/doi.org\/10.2147\/JHC.S428980","journal-title":"J Hepatocell Carcinoma"},{"issue":"11","key":"11380_CR14","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1016\/j.acra.2025.07.043","volume":"32","author":"J Zhang","year":"2025","unstructured":"Zhang J, Zu J (2025) Influencing factors and nomogram model construction of cancer-related fatigue in primary liver cancer patients post-TACE treatment. Acad Radiol 32(11):6570\u20136578. https:\/\/doi.org\/10.1016\/j.acra.2025.07.043","journal-title":"Acad Radiol"},{"key":"11380_CR15","doi-asserted-by":"publisher","unstructured":"Xu Y, Pan LR (2024) Effects of cluster nutrition intervention on nutritional status, cancer-related fatigue, and quality of life in mid-to-late stage liver cancer patients undergoing TACE. Chuan Bei Yi Xue Yuan Xue Bao 39(8):1148\u20131152. Chinese. https:\/\/doi.org\/10.3969\/j.issn.1005-3697.2024.08.034","DOI":"10.3969\/j.issn.1005-3697.2024.08.034"},{"key":"11380_CR16","first-page":"22","volume":"25","author":"Y Lu","year":"2014","unstructured":"Lu Y, Yan Q (2014) Effect of aerobic exercise on cancer-related fatigue in liver cancer patients. Zhong Guo Xian Dai Yi Sheng 25:22\u201325 (Chinese)","journal-title":"Zhong Guo Xian Dai Yi Sheng"},{"key":"11380_CR17","doi-asserted-by":"publisher","unstructured":"Zheng AB, Zhao AQ, Wu PX (2013) Effect of walking exercise on cancer-related fatigue in liver cancer patients. Jie Fang Jun Hu Li Za Zhi 30(8):72\u201374. Chinese. https:\/\/doi.org\/10.3969\/j.issn.1008-9993.2013.08.026","DOI":"10.3969\/j.issn.1008-9993.2013.08.026"},{"key":"11380_CR18","first-page":"118","volume":"42","author":"XY Zhao","year":"2021","unstructured":"Zhao XY (2021) Effect of solution-focused approach on postoperative cancer-related fatigue in liver cancer patients. Yang Sheng Bao Jian Zhi Nan 42:118\u2013119 (Chinese)","journal-title":"Yang Sheng Bao Jian Zhi Nan"},{"key":"11380_CR19","doi-asserted-by":"publisher","unstructured":"Fan YY (2019) Effect of mindfulness-based stress reduction on psychological resilience and cancer-related fatigue in advanced liver cancer patients]. Yi Xue Lin Chuang Yan Jiu 36(11):2190\u20132192. Chinese. https:\/\/doi.org\/10.3969\/j.issn.1671-7171.2019.11.036","DOI":"10.3969\/j.issn.1671-7171.2019.11.036"},{"issue":"12","key":"11380_CR20","first-page":"136","volume":"19","author":"TX Xin","year":"2021","unstructured":"Xin TX (2021) Clinical effect of Jianpi Xiaoji Decoction on cancer-related fatigue in liver cancer patients. Zhong Guo Yi Yao Zhi Nan 19(12):136\u2013137 (Chinese)","journal-title":"Zhong Guo Yi Yao Zhi Nan"},{"key":"11380_CR21","doi-asserted-by":"publisher","unstructured":"Ouyang ZW, Wu YH (2022) Clinical study of Jianpi Yangrong Decoction on postoperative cancer-related fatigue in primary liver cancer]. Zhong Wai Yi Xue Yan Jiu 20(11):4\u20138. Chinese. https:\/\/doi.org\/10.14033\/j.cnki.cfmr.2022.11.002","DOI":"10.14033\/j.cnki.cfmr.2022.11.002"},{"key":"11380_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132430","author":"EL Fite","year":"2024","unstructured":"Fite EL, Makary MS (2024) Transarterial chemoembolization treatment paradigms for hepatocellular carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16132430","journal-title":"Cancers (Basel)"},{"issue":"2","key":"11380_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.14218\/JCTH.2022.00293","volume":"11","author":"BY Zhong","year":"2023","unstructured":"Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL (2023) Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol 11(2):480\u2013489. https:\/\/doi.org\/10.14218\/JCTH.2022.00293","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"11380_CR24","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3892\/ol.2020.11399","volume":"19","author":"S Shimose","year":"2020","unstructured":"Shimose S, Kawaguchi T, Iwamoto H et al (2020) Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett 19(4):2667\u20132676. https:\/\/doi.org\/10.3892\/ol.2020.11399","journal-title":"Oncol Lett"},{"issue":"21","key":"11380_CR25","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.12998\/wjcc.v10.i21.7275","volume":"10","author":"SW Lee","year":"2022","unstructured":"Lee SW, Peng YC, Lien HC, Ko CW, Tung CF, Chang CS (2022) Clinical values of Barcelona Clinic Liver Cancer subgroup and up-to-7 criteria in intermediate stage hepatocellular carcinoma with transcatheter arterial chemoembolization. World J Clin Cases 10(21):7275\u20137284. https:\/\/doi.org\/10.12998\/wjcc.v10.i21.7275","journal-title":"World J Clin Cases"},{"issue":"2","key":"11380_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jimed.2021.02.008","volume":"4","author":"J Cun","year":"2021","unstructured":"Cun J, Xu Y, Li W, Zhao X (2021) Analysis of factors affecting the prognosis of transcatheter arterial chemoembolization for hepatitis B-related hepatocellular carcinoma. J Interv Med 4(2):66\u201370. https:\/\/doi.org\/10.1016\/j.jimed.2021.02.008","journal-title":"J Interv Med"},{"issue":"16","key":"11380_CR27","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.12998\/wjcc.v12.i16.2911","volume":"12","author":"FL Zhang","year":"2024","unstructured":"Zhang FL, Xu J, Jiang YH et al (2024) Liver abscess and tracheal fistula induced by transcatheter arterial chemoembolization for hepatocellular carcinoma: a case report. World J Clin Cases 12(16):2911\u20132916. https:\/\/doi.org\/10.12998\/wjcc.v12.i16.2911","journal-title":"World J Clin Cases"},{"issue":"2","key":"11380_CR28","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.223091","volume":"308","author":"X Li","year":"2023","unstructured":"Li X, Zhang Y, Wang X et al (2023) Predicting infectious complications after percutaneous thermal ablation of liver malignancies: a 12-year single-center experience. Radiology 308(2):e223091. https:\/\/doi.org\/10.1148\/radiol.223091","journal-title":"Radiology"},{"key":"11380_CR29","doi-asserted-by":"publisher","unstructured":"Bzeizi KI, Arabi M, Jamshidi N et al (2021) Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancers (Basel) 13(24). Published 2021 Dec 7. https:\/\/doi.org\/10.3390\/cancers13246172","DOI":"10.3390\/cancers13246172"},{"issue":"3","key":"11380_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00117-022-00972-1","volume":"62","author":"P Huppert","year":"2022","unstructured":"Huppert P (2022) Transarterial chemoembolization of hepatocellular carcinoma. Radiologe 62(3):225\u2013233. https:\/\/doi.org\/10.1007\/s00117-022-00972-1","journal-title":"Radiologe"},{"issue":"1172","key":"11380_CR31","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/bjr\/tqaf112","volume":"98","author":"A Yamamoto","year":"2025","unstructured":"Yamamoto A, Kageyama K, Jogo A et al (2025) Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus. Br J Radiol 98(1172):1290\u20131297. https:\/\/doi.org\/10.1093\/bjr\/tqaf112","journal-title":"Br J Radiol"},{"key":"11380_CR32","doi-asserted-by":"publisher","unstructured":"Li SF, Xu Y, Liu YY (2024) Application effect of whole-course diversified health education combined with humanistic care in advanced hepatocellular carcinoma patients. Ai Zheng Jin Zhan 22(5):524\u2013527,539. Chinese. https:\/\/doi.org\/10.11877\/j.issn.1672-1535.2024.22.05.14","DOI":"10.11877\/j.issn.1672-1535.2024.22.05.14"},{"key":"11380_CR33","doi-asserted-by":"publisher","unstructured":"Lee H, Park EY, Park KH (2025) Assessing cancer-related fatigue: Validation of the Korean version of the cancer fatigue scale among cancer survivors. Asia Pac J Oncol Nurs 12:100657. Published 2025 Dec. https:\/\/doi.org\/10.1016\/j.apjon.2025.100657","DOI":"10.1016\/j.apjon.2025.100657"},{"issue":"7","key":"11380_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-024-08615-y","volume":"32","author":"KF Keane","year":"2024","unstructured":"Keane KF, Wickstrom J, Livinski AA, Blumhorst C, Wang TF, Saligan LN (2024) The definitions, assessment, and dimensions of cancer-related fatigue: a scoping review. Support Care Cancer 32(7):457. https:\/\/doi.org\/10.1007\/s00520-024-08615-y","journal-title":"Support Care Cancer"},{"issue":"3","key":"11380_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3350\/cmh.2023.0202","volume":"29","author":"Y Cho","year":"2023","unstructured":"Cho Y, Choi JW, Kwon H et al (2023) Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clin Mol Hepatol 29(3):521\u2013541. https:\/\/doi.org\/10.3350\/cmh.2023.0202","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"11380_CR36","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3350\/cmh.2025.0724","volume":"31","author":"IC Lee","year":"2025","unstructured":"Lee IC, Wang HW, Teng W et al (2025) Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma. Clin Mol Hepatol 31(4):1213\u20131232. https:\/\/doi.org\/10.3350\/cmh.2025.0724","journal-title":"Clin Mol Hepatol"},{"key":"11380_CR37","doi-asserted-by":"publisher","unstructured":"Fisher MI, Cohn JC, Harrington SE, Lee JQ, Malone D (2022) Screening and assessment of cancer-related fatigue: a clinical practice guideline for health care providers. Phys Ther 102(9). https:\/\/doi.org\/10.1093\/ptj\/pzac120","DOI":"10.1093\/ptj\/pzac120"},{"issue":"3","key":"11380_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2023.100361","volume":"11","author":"W Xu","year":"2024","unstructured":"Xu W, Zhu Z, Yu J, Li J, Lu H (2024) Symptoms experienced after transcatheter arterial chemoembolization in patients with primary liver cancer: a network analysis. Asia Pac J Oncol Nurs 11(3):100361. https:\/\/doi.org\/10.1016\/j.apjon.2023.100361","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"5","key":"11380_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083228","volume":"14","author":"H Chen","year":"2024","unstructured":"Chen H, Lu H, Zhou H et al (2024) Modular multimodal hospital-home chain physical activity rehabilitation programme (3M2H-PARP) in liver cancer: a protocol for a randomised controlled trial. BMJ Open 14(5):e083228. https:\/\/doi.org\/10.1136\/bmjopen-2023-083228","journal-title":"BMJ Open"},{"key":"11380_CR40","doi-asserted-by":"publisher","unstructured":"Norbury A, Hauser TU, Fleming SM, Dolan RJ, Huys QJM (2024) Different components of cognitive-behavioral therapy affect specific cognitive mechanisms. Sci Adv 10(13):eadk3222. https:\/\/doi.org\/10.1126\/sciadv.adk3222","DOI":"10.1126\/sciadv.adk3222"},{"issue":"5","key":"11380_CR41","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1097\/JS9.0000000000001197","volume":"110","author":"J Yang","year":"2024","unstructured":"Yang J, Rhu J, Lim S et al (2024) Impact of virtual reality education on disease-specific knowledge and anxiety for hepatocellular carcinoma patient scheduled for liver resection: a randomized controlled study. Int J Surg 110(5):2810\u20132817. https:\/\/doi.org\/10.1097\/JS9.0000000000001197","journal-title":"Int J Surg"},{"issue":"3","key":"11380_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092","volume":"6","author":"J Arends","year":"2021","unstructured":"Arends J, Strasser F, Gonella S et al (2021) Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open 6(3):100092. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100092","journal-title":"ESMO Open"},{"issue":"4","key":"11380_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3760\/cma.j.issn.1674-2907.2019.04.021","volume":"25","author":"ML Qi","year":"2019","unstructured":"Qi ML, Liu YP, Xu X et al (2019) Status and influencing factors of cancer-related fatigue in postoperative primary liver cancer patients. Zhonghua Xian Dai Hu Li Za Zhi 25(4):477\u2013480. https:\/\/doi.org\/10.3760\/cma.j.issn.1674-2907.2019.04.021. (Chinese)","journal-title":"Zhonghua Xian Dai Hu Li Za Zhi"},{"key":"11380_CR44","doi-asserted-by":"publisher","unstructured":"George S, Devadas K, Thayyil Sudheendran P et al (2025) Effect of transarterial chemoembolization on health-related quality of life in patients with hepatocellular carcinoma. Cureus 17(4):e82531. Published 2025 Apr. https:\/\/doi.org\/10.7759\/cureus.82531","DOI":"10.7759\/cureus.82531"},{"key":"11380_CR45","doi-asserted-by":"publisher","unstructured":"Wang Q, Liu YX (2009) Nursing interventions for cancer-related fatigue in liver cancer patients]. Ji Ceng Yi Xue Lun Tan 13(33):970\u2013971. Chinese. https:\/\/doi.org\/10.3969\/j.issn.1672-1721.2009.33.008","DOI":"10.3969\/j.issn.1672-1721.2009.33.008"},{"issue":"3","key":"11380_CR46","doi-asserted-by":"publisher","first-page":"214","DOI":"10.14735\/amko2020214","volume":"33","author":"T Rohan","year":"2020","unstructured":"Rohan T, Uher M, Matkul\u010d\u00edk P et al (2020) Prognostic survival factors of hepatocellular carcinoma treated with transarterial chemoembolization. Klin Onkol 33(3):214\u2013219. https:\/\/doi.org\/10.14735\/amko2020214","journal-title":"Klin Onkol"},{"key":"11380_CR47","doi-asserted-by":"publisher","unstructured":"(2023) Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition). Zhonghua Yi Xue Za Zhi 103(34):2674\u20132694. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20230630-01114","DOI":"10.3760\/cma.j.cn112137-20230630-01114"},{"key":"11380_CR48","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.929884","volume":"27","author":"ZJ Wu","year":"2021","unstructured":"Wu ZJ, Xie YF, Chang X et al (2021) Type of necrosis influences prognosis in hepatocellular carcinoma after the first transarterial chemoembolization. Med Sci Monit 27:e929884. https:\/\/doi.org\/10.12659\/MSM.929884","journal-title":"Med Sci Monit"},{"key":"11380_CR49","doi-asserted-by":"publisher","unstructured":"Kassab I, Singal AG, Ali A et al (2023) Stage migration as a surrogate of survival in hepatocellular carcinoma treated with transarterial chemoembolization. Hepatol Commun 7(4). Published 2023 Apr 1. https:\/\/doi.org\/10.1097\/HC9.0000000000000091","DOI":"10.1097\/HC9.0000000000000091"},{"issue":"10","key":"11380_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202502566","volume":"15","author":"Y Liu","year":"2026","unstructured":"Liu Y, Liu J, Zheng C, Ma Z (2026) Recent advances in embolic agents for transarterial chemoembolization of hepatocellular carcinoma. Adv Healthc Mater 15(10):e02566. https:\/\/doi.org\/10.1002\/adhm.202502566","journal-title":"Adv Healthc Mater"},{"key":"11380_CR51","doi-asserted-by":"publisher","unstructured":"(2022) Expert consensus on transarterial chemoembolization refractoriness and subsequent therapies in hepatocellular carcinoma. Zhonghua Nei Ke Za Zhi 61(8):860\u2013866. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20220615-00452","DOI":"10.3760\/cma.j.cn112138-20220615-00452"},{"issue":"5","key":"11380_CR52","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR, Wang XS, Cleeland CS et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186\u20131196","journal-title":"Cancer"},{"issue":"4","key":"11380_CR53","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jpainsymman.2003.09.008","volume":"27","author":"XS Wang","year":"2004","unstructured":"Wang XS, Hao XS, Wang Y et al (2004) Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). J Pain Symptom Manage 27(4):322\u2013332. https:\/\/doi.org\/10.1016\/j.jpainsymman.2003.09.008","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"11380_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0885-3924(99)00138-4","volume":"19","author":"T Okuyama","year":"2000","unstructured":"Okuyama T, Akechi T, Kugaya A et al (2000) Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 19(1):5\u201314. https:\/\/doi.org\/10.1016\/S0885-3924(99)00138-4","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"11380_CR55","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1186\/s12885-025-14829-y","volume":"25","author":"C Robinson","year":"2025","unstructured":"Robinson C, Feder G, Huntley AL et al (2025) Validation of the cancer fatigue scale (CFS) in a UK population. BMC Cancer 25(1):1394. https:\/\/doi.org\/10.1186\/s12885-025-14829-y","journal-title":"BMC Cancer"},{"issue":"3","key":"11380_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","volume":"39","author":"EM Smets","year":"1995","unstructured":"Smets EM, Garssen B, Bonke B, De Haes JC (1995) The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39(3):315\u2013325. https:\/\/doi.org\/10.1016\/0022-3999(94)00125-O","journal-title":"J Psychosom Res"},{"issue":"10","key":"11380_CR57","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s00520-011-1357-8","volume":"20","author":"J Tian","year":"2012","unstructured":"Tian J, Hong JS (2012) Validation of the Chinese version of multidimensional fatigue inventory-20 in Chinese patients with cancer. Support Care Cancer 20(10):2379\u20132383. https:\/\/doi.org\/10.1007\/s00520-011-1357-8","journal-title":"Support Care Cancer"},{"key":"11380_CR58","doi-asserted-by":"publisher","first-page":"1062426","DOI":"10.3389\/fpsyt.2022.1062426","volume":"13","author":"A Westenberger","year":"2022","unstructured":"Westenberger A, N\u00f6hre M, Br\u00e4hler E, Morfeld M, de Zwaan M (2022) Psychometric properties, factor structure, and German population norms of the multidimensional fatigue inventory (MFI-20). Front Psychiatry 13:1062426. https:\/\/doi.org\/10.3389\/fpsyt.2022.1062426","journal-title":"Front Psychiatry"},{"key":"11380_CR59","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 2.2025. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=28.\u00a0Accessed 2 Oct 2026"},{"issue":"6","key":"11380_CR60","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","volume":"31","author":"A Fabi","year":"2020","unstructured":"Fabi A, Bhargava R, Fatigoni S et al (2020) Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment. Ann Oncol 31(6):713\u2013723. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.016","journal-title":"Ann Oncol"},{"issue":"7","key":"11380_CR61","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","volume":"3","author":"KM Mustian","year":"2017","unstructured":"Mustian KM, Alfano CM, Heckler C et al (2017) Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 3(7):961\u2013968. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6914","journal-title":"JAMA Oncol"},{"issue":"12","key":"11380_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08130-6","volume":"31","author":"OA Agbejule","year":"2023","unstructured":"Agbejule OA, Chan RJ, Ekberg S, Ashbury FD, Kleckner AS, Hart NH (2023) Cancer-related fatigue self-management: a MASCC-endorsed practice framework for healthcare professionals to optimally support cancer survivors. Support Care Cancer 31(12):666. https:\/\/doi.org\/10.1007\/s00520-023-08130-6","journal-title":"Support Care Cancer"},{"issue":"1","key":"11380_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijnss.2023.09.009","volume":"11","author":"T Pathomjaruwat","year":"2024","unstructured":"Pathomjaruwat T, Matchim Y, Armer JM (2024) Symptoms and symptom clusters in patients with hepatocellular carcinoma and commonly used instruments: an integrated review. Int J Nurs Sci 11(1):66\u201375. https:\/\/doi.org\/10.1016\/j.ijnss.2023.09.009","journal-title":"Int J Nurs Sci"},{"key":"11380_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19135-y","volume":"15","author":"J Li","year":"2025","unstructured":"Li J, Lin S, She Z, Lu W, Liang Z, Tan Y (2025) Exploring the heterogeneity of cancer-related fatigue in advanced hepatocellular carcinoma patients via latent profiles and influencing factors. Sci Rep 15:35151. https:\/\/doi.org\/10.1038\/s41598-025-19135-y","journal-title":"Sci Rep"},{"issue":"12","key":"11380_CR65","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","volume":"39","author":"SC Bischoff","year":"2020","unstructured":"Bischoff SC, Bernal W, Dasarathy S et al (2020) ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr 39(12):3533\u20133562. https:\/\/doi.org\/10.1016\/j.clnu.2020.09.001","journal-title":"Clin Nutr"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11380-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11380-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:01:53Z","timestamp":1792792913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11380-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11380"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11380-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is a narrative review based on published literature and does not involve human participants or animal subjects. Therefore, ethical approval was not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (narrative review).","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (narrative review).","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1148"}}